Martin B. Pavane, Vice Chair, Intellectual Property Department, Co-Chair, ANDA & Biologics Practice Group, Cozen O'Connor to Speak at TKG’s Event
New York, NY, December 14, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Martin B. Pavane, Vice Chair, Intellectual Property Department, Co-Chair, ANDA & Biologics Practice Group, Cozen O'Connor will speak at the Knowledge Group’s webcast entitled: “The Hatch-Waxman Act: Recent Amendments and Developments Live Webcast.” This event is scheduled for December 14, 2017 at 12:00 PM - 1:30 PM ET.
For further details, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About Martin B. Pavane
Martin B. Pavane, Vice Chair of Cozen O’Connor’s Intellectual Property Department, is a litigator and registered patent attorney with more than 30 years of experience litigating intellectual property cases. He has been lead trial counsel in many patent, trademark and copyright cases throughout the United States, including many jury trials. At Cozen O’Connor, Martin currently holds the titles of vice chair of the Intellectual Property practice group and co-chair of the ANDA and Biologics practice group, and he is also on the Board of Directors of the firm. He has been named a New York Super Lawyer in intellectual property litigation since the inception of that designation. During the early part of his career, Martin practiced extensively before the U.S. Patent and Trademark Office, where he prosecuted patent applications and handled appeals before the Board of Patent Appeals and Interferences.
About Cozen O'Connor
Established in 1970 and ranked among the top 100 law firms in America, Cozen O’Connor has more than 650 attorneys who help clients manage risk and make better business decisions. The firm counsels clients on their most sophisticated legal matters in all areas of the law, including litigation, corporate and regulatory law. Representing a broad array of leading global corporations and middle market companies, Cozen O’Connor services its clients’ needs through 25 offices across two continents.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications - approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This Live webcast will discuss the following key topics:
The Hatch-Waxman Act: Overview and Legal Framework
Latest Developments
The Abbreviated New Drug Application (ANDA) Process
Latest Developments in ANDA Litigation
Recent FDA Applications
The Hatch-Waxman Act in 2018 – An Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About Martin B. Pavane
Martin B. Pavane, Vice Chair of Cozen O’Connor’s Intellectual Property Department, is a litigator and registered patent attorney with more than 30 years of experience litigating intellectual property cases. He has been lead trial counsel in many patent, trademark and copyright cases throughout the United States, including many jury trials. At Cozen O’Connor, Martin currently holds the titles of vice chair of the Intellectual Property practice group and co-chair of the ANDA and Biologics practice group, and he is also on the Board of Directors of the firm. He has been named a New York Super Lawyer in intellectual property litigation since the inception of that designation. During the early part of his career, Martin practiced extensively before the U.S. Patent and Trademark Office, where he prosecuted patent applications and handled appeals before the Board of Patent Appeals and Interferences.
About Cozen O'Connor
Established in 1970 and ranked among the top 100 law firms in America, Cozen O’Connor has more than 650 attorneys who help clients manage risk and make better business decisions. The firm counsels clients on their most sophisticated legal matters in all areas of the law, including litigation, corporate and regulatory law. Representing a broad array of leading global corporations and middle market companies, Cozen O’Connor services its clients’ needs through 25 offices across two continents.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications - approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This Live webcast will discuss the following key topics:
The Hatch-Waxman Act: Overview and Legal Framework
Latest Developments
The Abbreviated New Drug Application (ANDA) Process
Latest Developments in ANDA Litigation
Recent FDA Applications
The Hatch-Waxman Act in 2018 – An Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories